Your shopping cart is currently empty

FATP1-IN-1 is a potent inhibitor of fatty acid transport protein 1 (FATP1). It effectively inhibits the activity of recombinant human or mouse acyl-CoA synthetase, which is essential for the function of FATP1. The inhibition is characterized by IC50 values of 0.046 μM for human FATP1 and 0.60 μM for mouse FATP1.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $79 | In Stock | In Stock | |
| 5 mg | $198 | In Stock | In Stock | |
| 10 mg | $328 | In Stock | In Stock | |
| 25 mg | $562 | In Stock | In Stock | |
| 50 mg | $786 | In Stock | In Stock | |
| 100 mg | $1,090 | - | In Stock | |
| 1 mL x 10 mM (in DMSO) | $226 | In Stock | In Stock |
| Description | FATP1-IN-1 is a potent inhibitor of fatty acid transport protein 1 (FATP1). It effectively inhibits the activity of recombinant human or mouse acyl-CoA synthetase, which is essential for the function of FATP1. The inhibition is characterized by IC50 values of 0.046 μM for human FATP1 and 0.60 μM for mouse FATP1. |
| In vivo | FATP1-IN-1 administered orally (p.o.) at a dosage of 10 mg/kg demonstrated pharmacokinetic parameters with a maximum concentration (C max) of 5.5 μg/mL, an area under the curve (AUC) of 36 μg h/mL, and a time to reach maximum concentration (T max) of 0.33 hours. These results were attained in a mouse plasma [1] model and surpassed the IC 50 value of 0.22 μM for mice, without accounting for plasma protein binding. |
| Synonyms | FATP1-IN-1 |
| Molecular Weight | 375.46 |
| Formula | C18H22FN5OS |
| Cas No. | 1431945-95-7 |
| Smiles | Fc1ccc(nc1)N1CCN(CC(=O)Nc2nc3CCCCc3s2)CC1 |
| Relative Density. | 1.349 g/cm3 (Predicted) |
| Storage | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 56.2 mg/mL (149.68 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (5.33 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.